1 / 36

Give simply more

Give simply more. What is PraxisPlatform ?. PraxisPlatform is an ICT-supported* patient communication platform which is focused on: sending therapy-related information to patients to increase their adherence/compliance in medicinal therapy and medical device use

bena
Download Presentation

Give simply more

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Givesimply more

  2. What is PraxisPlatform? PraxisPlatform is an ICT-supported* patient communication platform which is focused on: sending therapy-related information to patients to increase their adherence/compliance in medicinal therapy and medical device use enabling pharmacy care services to large patient populations Wehavesuccessfully commercialized a streamlined platform which brings more health to patients, more revenue to pharma and medical device companies and savings to payers. * ICT – Information and communication technology

  3. 3 Aboutthecompany PraxisPlatform has been developed by health economists and managed care experts in Central Europe, a challenging environment characterized by limited health care resources and low health consciousness of the population. Weemploy a staff of about 30 peopleinBudapest, specialized in thefollowingareas: • Clinical content development • Sales & Marketing • Customer service (incl. call center) • IT development

  4. 4 PraxisPlatform has been throughfouryears of quick expansion In December 2012, PraxisPlatform teams up with one of the leading Hungarian pharmacy chains to offer pharmacy care services and to manage its client loyalty programme In Summer 2013, the100.000thpatientis registered In May 2011, PraxisPlatform and Magyar Telekom sign a commercial deal and Magyar Telekom markets the product in Hungary Sincethenprojects are launched every month in patient adherence management. After some years at the Hungarian sick fund, a small team of committedprofessionalsstartstodevelopPraxisPlatformin June 2010 In 2013, PraxisPlatformlaunches a diseaseregistrymoduleand offers a transplantationregistry By early 2012, PraxisPlatform is able to offer complex market research servicesand launches its real-life evidence generation module (non-interventional studies) In December 2010, the first pilot project in patient adherence management starts in co-operation with the Hungarian subsidiary of Deutsche Telekom group and Sanofi-Aventis

  5. 5 PraxisPlatform in figures (1 Feb 2014) 25 Companies 60% of all potential partners 4.700 Physicians 30% of all active physicians, 1.500 active users* 112 Pharmacies ** 112.000 Patients Wentlive 1 Oct 2010 Geographies Hungary 5 Modules*** 50 Programmes * Inactivephysicianswhohavecontractedwith PraxisPlatform, can be reachedby PraxisPlatform, buthavenotenrolledanypatientstoprogrammesyet. Theyarestilllearningsystemfunctionsorwaitingfortheappropriateprogrammefortheirpatients. ** In co-operation with one of the largest Hungarian pharmacy chains *** Patienteducation and pharmacycare, market research, clinical trial, patient registry, screening

  6. 6 Real-life evidencegeneration (NIS, PAES, MES/PAS)* Patienteducation and pharmacycare Diseaseregistries What services are currently offeredbyPraxisPlatform? Patientscreening Primary market research Pharmaco-vigilance Data mining E-detailing Coremodule Independent module Additionalservices * NIS: Phase IV non-interventionaltrials, PAES: Post-authorization efficacy studies , MES/PAS: Managedentry schemes / patientaccessschemes

  7. 7 Currentsituation of PraxisPlatform 1 • PraxisPlatform has reached a dominant position in Hungary, a Central European EU member state of 10 million people where further growth opportunities are limited because of the size of the country • The value of Hungary is that it is often used as a test market by Big Pharma: if an idea works in Hungary, it is likely to work in several other markets • PraxisPlatform has an infrastructure to service more patients, physicians and doctors in more geographies • PraxisPlatform has the clinical, ICT and sales know-how which can be transferred to absolutely different regions • PraxisPlatform is an integrated platform which is difficult to copy: individually existing separate modules do not pose a threat to the business concept • PraxisPlatform has IRP protection for the EU • PraxisPlatform isinterested in TECHNOLOGYTRANSFERto major geographies with developed health care markets 2 • PraxisPlatform isinterested in COMMERCIALIZATION AGREEMENTS to extend its services to other regions

  8. PraxisPlatform –Technology transfer and commercialization deal opportunity Commercialization („service”) Vermarktung („Dienstleistung”) Technology transfer („clone”) • In this model, we commit ourselves to operating PraxisPlatform with a business partner who wishes to introduce this service in a new geography • We co-develop the business model, we carry out the necessary modifications and we maintain active involvement in operations via our service center in Budapest • All rights stay with us, and we set up a revenue or profit sharing scheme with the commercial partner • PraxisPlatform has been developed with approx. 50.000 IT developer hours over 3 years • Based on our experience and knowhow, our team is able to develop and test a clone of our system in 3-4 months • In this model, our team builds, test and launches the clone and trains the buyer • We are not involved in further operations and all rights stay with the buyer for the relevant geography

  9. AbouttheEducationalprogrammes

  10. 10 Starting point: Non-adherence, the most devastatingillness of the modern world Source: Dankó – Frang – Molnár: Patients’ adherence to statin treatment. Corvinus University of Budapest, 2010, n= 459.034, based on National Health Insurance Fund financial database, 2007.01.01 – 2009.12.31

  11. 11 The key goal of PraxisPlatform is to help, educate and empower • Communication • tool and content • Other • Services Product Kommunikációseszköz és tartalom Egyéb szolgáltatások Termék Motivated, health-conscious and satisfied patient, who is healthier

  12. 12 Howeducationalprogrammes work… HEALTH CARE COMPANIES They commission PraxisPlatform to (co-)develop therapy management, adherence management and pharmacy care programmes for their products and services. PraxisPlatform usually works together with pharma and medical device companies but health insurers, patient advocacy groups and clinical organizations are also valued clients. PHYSICIANS PHARMACISTS They enrol patients (customers) into the programmes offered by PraxisPlatform. They receive feedback about their patients’ health behaviour. They are remunerated proportionally to their workload in a legal and ethical way. They enrol patients (customers) into the programmes offered by PraxisPlatform. They receive feedback about their patients’ health behaviour. They are remunerated proportionally to their workload in a legal and ethical way. PATIENTS Patients receive therapy-related information, general health information, pharmacy care information and eventually nursing and along an optimized timeline. Patients receive all services without payment. Patients can contact their physician and pharmacist via PraxisPlatform. Patients form patient communities.

  13. 13 Casestudy 1: supportingthelaunch of an originaldrug Combinationproductforthetreatment of benignprostatichypertrophy Activesubstance: dutasteride+tamsulosine Programmedurationforeachpatient: 6 months Segmentationfee: 6.5 euro Targetgroup: urologists(approx. 300 registeredspecialists) Goal: supporttofieldactivityuponproductlaunch

  14. 14 Briefsummary of theresults Persistenceimprovement is between 15 and 20 percent. Activegroup: patientswhohavereceivedfulleducation. Controlgroup: patientswhohavenotreceivedfulleducation.

  15. 15 Casestudy 2: Replacing sales activities for an off-patentedoriginaldrug The programmewaslaunchedforpatientswhoreceivedlipid-loweringtherapybecause of theirpathodologicallyhightrigliceridelevel and unfavourablecholesterollevel. Activesubstance: fenofibrate Programmeduration: 6 months Segmentationfee: 3.5 euro Number of enrolledpatients: 5045 Medicaltargetgroup is toowideto be coveredbyfieldforce: more than 2000 doctors, incl. internalmedicinespecialists, GP’s and cardiologists Goal:subsitution of fieldforceactivitywhilemaintainingthe market position of theproduct

  16. 16 Briefsummary of theresults Wehavedataaboutpatientpersistenceinfibratelipid-loweringtherapyin Hungary. The analysis is basedonthedata of theHungarian National healthInsuranceFundAdministration.. Source: Molnár M. P. – Pálosi M. (2012): Patientadherence (persistence) infibratelipid-loweringtherapy, MedicalTribune, October2012 The persistencecurvefortheactivegroup is basedon a random phonesurveyinwhich a representativesample of 100 enrolledpatients (basedonage, gender and residence) wasinterviewedabouttheirmedication-takinghabits. Persistenceincreased more thantwofold. 75 per cent of patientswereonnewlyinitiatedtherapy. As a result, salesstabilised and showed an increase of 2 per cent despitethecancellation of allfieldforceactivities.

  17. 17 Casestudy 3: replacingsalesacitiviesfor an off-patentedoriginaldrug The programmewasdesignedforpatientswhosufferfrom osteoporosis. Ithelpsthempossess a deeperknowledge of thedisease and followmedicinaltherapy more properly. Activesubtance: alendronicacid Programmedurationforpatients: 7.5 months Segmentationfee: 6.5 euro Medicaltargetgroup: widescope of physicians (GP’s, orthopedicsurgeons, traumatologists, rheumatologists Goal: substitution of fieldforceactivity, protection of market positions

  18. Briefsummary of theresults Wehavedataaboutpatientpersistenceinoralbisphosphonatetherapyin Hungary. The analysis is basedonthedata of theHungarian National healthInsuranceFundAdministration.. The persistencecurvefortheactivegroup is basedon a random phonesurveyinwhich a representativesample of 100 enrolledpatients (basedonage, gender and residence) wasinterviewedabouttheirmedication-takinghabits. Persistenceincreased almost twofold. 78 per cent of patientswereonnewlyinitiatedtherapy. As a result, thedownward trend of saleswashalted and stabilized.

  19. 19 Casestudy 4: supporting an oncologicaloriginaldrug The programmewasdesignedforpatientssufferingfrom HER2+ metastaticbreastcancer. Activesubstance: Lapatinib Porgrammedurationforpatients: 6 months Segmentationfee: none Goal: Toenablephysicianstohelptheirbreastcancerpatientsbettercopewiththeircondition and followmedicinaltherapy more properly, withspecialregardtoeventualsideeffects Medicaltargetgroup: clinicaloncologists The programmeofferedcomprehensivemedicalcareincludingpersonalvisitsatthepatient’shome.

  20. Briefsummary of theresults Althoughtheprogrammewasnotexpectedtoprolongtherapydurationwithend-stagepatients, suchimprovementwasinfactregistered. This is attributabletotheappropriate management of sideeffectduringtherapy.

  21. 21 Programmes and therapeuticareas Range of therapeuticareascoveredbyPraxisPlatform: • Hypertension • Incontinence (diaper) • Asthma • Prostatehypertrophy • Anticoagulanttherapy • Parinson’s • COPD • Breastcancer • Arthrosis • Depression • Hyperlipidaemia • HPV treatment • Heartfailure/angina pectoris • Stroke • Diabetes mellitus (measurement) • Osteoporosis • Gastrooesophagialis reflux • Chronicmyeloidleukaemia • Allergy • Erectiledysfunction • Cachexia-anorexia – oncology • Diabetes mellitus • Cardiovasculardisease • Metabolicsyndrome • Health promotion/prevention • Pregnancy • Probiotics • InflammatoryBowelDisease

  22. 22 Parts of educationalprogrammes Basic programmedata Deadlines, goals and therapy, sponsoringhealthcarecompany, financing, description, programmemessages Informationleafletforphysicians abouttherapy & drug, howtoenrolpatients in a programme Informationleafletforpatients abouttherapy & drug; suggestionsforthetherapy Programmemessages Patientscanread (orlistento) allprogrammemessages (email, text, recordedvoicemessage) alreadysentby PraxisPlatform. Forphysiciansallprogrammemessagesareavailable. Quiz The quiz is dedicated to patients in a specific programme and consists of questions about the therapy, providing a possibility for the patient to test his or her knowledge about the therapy. Questionnaire At the end of a programme, patients can fill in a satisfaction surveyserving for the evaluation of the programme. Diary Patients in a programme can fill in a daily or weekly ‚diary’ consisting of questions about the specific therapy and/or thepatient’smedical condition. The patient’sphysiciancanreadthediaryentries. Statistics Statistics about the patients in the programme Patientcalls In certain programmes, the involved physician has to carry out consultations with the patient via phone call.

  23. About market research

  24. 24 Market research Physicians can be enrolled into programme-specific or programme-independent market research. They are compensatedfor filling in the market research questionnaire.

  25. Aboutclinicaltrials

  26. 26 Clinicaltrials WithinPraxisPlatform’sreal-life evidence generation module, physicians can be invitedto program-specific or program-independent, prospective, non-interventionalclinicalstudies. The PraxisPlatform system is able to manage the whole process of a clinical trial from enrolling a patient into the trial through filling out the visit data up to handling the financial processes (both physicians and supporting health care company).

  27. AboutDiseaseRegistries

  28. 28 Diseaseregistry PraxisPlatform offers to specific therapeutic areas diseaseregistries with the following main functions: • invited physicians can enrol their patients into a registry • in the registry module, they can fill in visit questionnaires • physicians are notified about recommended patient visits via email • patients can also be notified about recommended visits via email, text message or voice message • the module can handle the financial processes related to the physician's activity

  29. 29 Transplantregistry The transplant registry is a specific patient registry enablingphysicians working at a transplant institute to enrol their patients as recipients in the transplant registry to enter transplant-specific donor data into the donor database to fill in all relevant medical data of transplant operations.

  30. BenefitsofferedbyPraxisPlatformtoitsClients

  31. 31 How do patients benefit from PraxisPlatformTM? • Free access to all patient features of PraxisPlatformTM • Guidance to take medicines and use medical devices properly • Guidance on lifestyle, health behavior and adherence to therapy • Easy-to-access web content about disease and treatment • Additional, flexible contact with treating specialist • Comprehensive call center support (active and passive) • Web-based patient communities • In certain programmes: totally interactive features • Patient retention is 98% in our running programmes

  32. 32 What are physicians’ and pharmacists’ benefits? • Free access to all core modules • Easy and tailor-made communication with patients, saving time and reducing workload • Possibility to access large populations at no cost* • Access to a comprehensive range of ready-to-send programmes uploaded by pharmaceutical and medical device companies • Telemedicine and virtual chronic care features • Possibility to participate in clinical research and market surveys • Remuneration proportional to time spent on data management • Feedback on patients’ adherence and drug consumption

  33. 33 Benefits offered by PraxisPlatform to health care companies Clinicalbenefits Commercialbenefits • Stronger adherence to treatment, better utilization of proprietary health technologies • Higher real-life therapeutic effectiveness • Lower risk of switches and therapy discontinuation • Possibility to participate in patient education • Increasing revenues • Higher adherence / persistence • Higher brand awareness • Higher perceived drugvalue • Balanced marketing channel mix • Favorable programmecost structure • Low costs of reaching patients • Targeted, flexible campaigns

  34. Major references of PraxisPlatform

  35. 35 Major references of PraxisPlatform

  36. Contact: info@praxisplatform.hu

More Related